Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome

Babak Nazer, Kausik K. Ray, Sarah Sloan, Benjamin Scirica, David A. Morrow, Christopher P. Cannon, Eugene Braunwald

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Aims There is increasing evidence that immune mechanisms are involved in the pathogenesis of heart failure (HF). The relationship between neopterin and the risk of HF has yet to be investigated on a large scale. We assessed the relationship between neopterin, a novel marker of monocyte activation, and risk of hospitalization for HF. Methods and resultsAmong the subjects of Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial, 3946 had neopterin levels measured at study entry, on average 7 days after acute coronary syndrome (ACS). We assessed the relationship between neopterin and hospitalization for HF, and for death or HF over 2 years mean follow-up in a post hoc analysis using Cox regression models. Unadjusted hospitalization rates for HF increased across quartiles of neopterin, from 0.66 to 3.97 per 100 person-years. Per 1SD increment in log (neopterin), the adjusted risk of HF increased by 34 [hazard ratio (HR) 1.34, CI 1.101.64; P = 0.004]. Even after excluding individuals with a prior history of HF or recurrent ischaemic events, the relationship between neopterin and HF hospitalization remained significant. When added to a multivariable Cox model of HF-risk containing traditional risk factors, C-reactive protein and brain natriuretic protein (BNP), the further addition of neopterin significantly improved the HF-risk prediction model by likelihood ratio test analysis (P = 0.005), C-statistic (increasing from 0.743 to 0.773; P = 0.027), integrated discrimination improvement (IDI) analysis (P = 0.001), but not net reclassification improvement (NRI) analysis (P = 0.406). Similar results were obtained for the endpoint of death or HF. Conclusion Neopterin levels are an independent predictor of HF hospitalization, and improve risk prediction over and above conventional biomarkers.

Original languageEnglish (US)
Pages (from-to)1390-1397
Number of pages8
JournalEuropean Heart Journal
Volume32
Issue number11
DOIs
StatePublished - Jun 2011
Externally publishedYes

Fingerprint

Neopterin
Acute Coronary Syndrome
Hospitalization
Heart Failure
Proportional Hazards Models
Pravastatin
C-Reactive Protein

Keywords

  • Biomarkers
  • Heart failure
  • Prognosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. / Nazer, Babak; Ray, Kausik K.; Sloan, Sarah; Scirica, Benjamin; Morrow, David A.; Cannon, Christopher P.; Braunwald, Eugene.

In: European Heart Journal, Vol. 32, No. 11, 06.2011, p. 1390-1397.

Research output: Contribution to journalArticle

Nazer, Babak ; Ray, Kausik K. ; Sloan, Sarah ; Scirica, Benjamin ; Morrow, David A. ; Cannon, Christopher P. ; Braunwald, Eugene. / Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. In: European Heart Journal. 2011 ; Vol. 32, No. 11. pp. 1390-1397.
@article{818234f74d5f4f73b7ca30116365dc9a,
title = "Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome",
abstract = "Aims There is increasing evidence that immune mechanisms are involved in the pathogenesis of heart failure (HF). The relationship between neopterin and the risk of HF has yet to be investigated on a large scale. We assessed the relationship between neopterin, a novel marker of monocyte activation, and risk of hospitalization for HF. Methods and resultsAmong the subjects of Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial, 3946 had neopterin levels measured at study entry, on average 7 days after acute coronary syndrome (ACS). We assessed the relationship between neopterin and hospitalization for HF, and for death or HF over 2 years mean follow-up in a post hoc analysis using Cox regression models. Unadjusted hospitalization rates for HF increased across quartiles of neopterin, from 0.66 to 3.97 per 100 person-years. Per 1SD increment in log (neopterin), the adjusted risk of HF increased by 34 [hazard ratio (HR) 1.34, CI 1.101.64; P = 0.004]. Even after excluding individuals with a prior history of HF or recurrent ischaemic events, the relationship between neopterin and HF hospitalization remained significant. When added to a multivariable Cox model of HF-risk containing traditional risk factors, C-reactive protein and brain natriuretic protein (BNP), the further addition of neopterin significantly improved the HF-risk prediction model by likelihood ratio test analysis (P = 0.005), C-statistic (increasing from 0.743 to 0.773; P = 0.027), integrated discrimination improvement (IDI) analysis (P = 0.001), but not net reclassification improvement (NRI) analysis (P = 0.406). Similar results were obtained for the endpoint of death or HF. Conclusion Neopterin levels are an independent predictor of HF hospitalization, and improve risk prediction over and above conventional biomarkers.",
keywords = "Biomarkers, Heart failure, Prognosis",
author = "Babak Nazer and Ray, {Kausik K.} and Sarah Sloan and Benjamin Scirica and Morrow, {David A.} and Cannon, {Christopher P.} and Eugene Braunwald",
year = "2011",
month = "6",
doi = "10.1093/eurheartj/ehr032",
language = "English (US)",
volume = "32",
pages = "1390--1397",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome

AU - Nazer, Babak

AU - Ray, Kausik K.

AU - Sloan, Sarah

AU - Scirica, Benjamin

AU - Morrow, David A.

AU - Cannon, Christopher P.

AU - Braunwald, Eugene

PY - 2011/6

Y1 - 2011/6

N2 - Aims There is increasing evidence that immune mechanisms are involved in the pathogenesis of heart failure (HF). The relationship between neopterin and the risk of HF has yet to be investigated on a large scale. We assessed the relationship between neopterin, a novel marker of monocyte activation, and risk of hospitalization for HF. Methods and resultsAmong the subjects of Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial, 3946 had neopterin levels measured at study entry, on average 7 days after acute coronary syndrome (ACS). We assessed the relationship between neopterin and hospitalization for HF, and for death or HF over 2 years mean follow-up in a post hoc analysis using Cox regression models. Unadjusted hospitalization rates for HF increased across quartiles of neopterin, from 0.66 to 3.97 per 100 person-years. Per 1SD increment in log (neopterin), the adjusted risk of HF increased by 34 [hazard ratio (HR) 1.34, CI 1.101.64; P = 0.004]. Even after excluding individuals with a prior history of HF or recurrent ischaemic events, the relationship between neopterin and HF hospitalization remained significant. When added to a multivariable Cox model of HF-risk containing traditional risk factors, C-reactive protein and brain natriuretic protein (BNP), the further addition of neopterin significantly improved the HF-risk prediction model by likelihood ratio test analysis (P = 0.005), C-statistic (increasing from 0.743 to 0.773; P = 0.027), integrated discrimination improvement (IDI) analysis (P = 0.001), but not net reclassification improvement (NRI) analysis (P = 0.406). Similar results were obtained for the endpoint of death or HF. Conclusion Neopterin levels are an independent predictor of HF hospitalization, and improve risk prediction over and above conventional biomarkers.

AB - Aims There is increasing evidence that immune mechanisms are involved in the pathogenesis of heart failure (HF). The relationship between neopterin and the risk of HF has yet to be investigated on a large scale. We assessed the relationship between neopterin, a novel marker of monocyte activation, and risk of hospitalization for HF. Methods and resultsAmong the subjects of Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trial, 3946 had neopterin levels measured at study entry, on average 7 days after acute coronary syndrome (ACS). We assessed the relationship between neopterin and hospitalization for HF, and for death or HF over 2 years mean follow-up in a post hoc analysis using Cox regression models. Unadjusted hospitalization rates for HF increased across quartiles of neopterin, from 0.66 to 3.97 per 100 person-years. Per 1SD increment in log (neopterin), the adjusted risk of HF increased by 34 [hazard ratio (HR) 1.34, CI 1.101.64; P = 0.004]. Even after excluding individuals with a prior history of HF or recurrent ischaemic events, the relationship between neopterin and HF hospitalization remained significant. When added to a multivariable Cox model of HF-risk containing traditional risk factors, C-reactive protein and brain natriuretic protein (BNP), the further addition of neopterin significantly improved the HF-risk prediction model by likelihood ratio test analysis (P = 0.005), C-statistic (increasing from 0.743 to 0.773; P = 0.027), integrated discrimination improvement (IDI) analysis (P = 0.001), but not net reclassification improvement (NRI) analysis (P = 0.406). Similar results were obtained for the endpoint of death or HF. Conclusion Neopterin levels are an independent predictor of HF hospitalization, and improve risk prediction over and above conventional biomarkers.

KW - Biomarkers

KW - Heart failure

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=79958145754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958145754&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehr032

DO - 10.1093/eurheartj/ehr032

M3 - Article

VL - 32

SP - 1390

EP - 1397

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 11

ER -